Nanobiotix S A Quick Ratio (NBTX) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nanobiotix S a   (NASDAQ: NBTX)

Nanobiotix S A 's Quick Ratio

NBTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.92 below Nanobiotix S A 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 338 other companies have achieved higher Quick Ratio than Nanobiotix S A in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1768, from total ranking in the third quarter 2025 at 2013.

Explain Quick Ratio?
How much Cash & cash equivalents NBTX´s has?
What are NBTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBTX Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -2.42 % -2.42 % -2.42 % -2.42 % 18.17 %
Y / Y Cash & cash equivalent Change 6.06 % 6.06 % 6.06 % 6.06 % -33.93 %
Quick Ratio MRQ 0.92 0.92 0.92 0.92 0.84
NBTX's Total Ranking # 1768 # 2013 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % -2.42 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 6.06 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 339
Healthcare Sector # 618
Overall Market # 1768


Quick Ratio Statistics
High Average Low
6.26 2.15 0.84
(Dec 31 2020)   (Dec 31 2024)




Financial Statements
Nanobiotix S A 's Current Liabilities $ 64 Millions Visit NBTX's Balance sheet
Nanobiotix S A 's Cash & cash equivalent $ 59 Millions Visit NBTX's Balance sheet
Source of NBTX's Sales Visit NBTX's Sales by Geography


Cumulative Nanobiotix S A 's Quick Ratio

NBTX's Quick Ratio for the trailling 12 Months

NBTX Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -2.42 % 2.11 % 7.02 % 12.35 % 18.17 %
Y / Y Cash & cash equivalent TTM Growth 6.06 % -7.35 % -18.02 % -26.72 % -33.93 %
Quick Ratio TTM 0.92 0.9 0.88 0.86 0.84
Total Ranking TTM # 4581 # 3631 # # #
Seq. Current Liabilities TTM Growth -0.62 % -0.61 % -0.61 % -0.61 % 4 %
Seq. Cash & cash equivalent TTM Growth 1.45 % 1.47 % 1.49 % 1.51 % -11.38 %

Quick ratio ranking by company, industry and sector >> Back to NBTX Financial Strength Comparisons >> Go to Compare NBTX Quick Ratio to its Competitors

  News about Nanobiotix S a Quick Ratio

Nanobiotix Hits $20M Milestone Payment in Global Phase 3 Head and Neck Cancer Study



Nanobiotix, a leading biotechnology company specializing in physics-based approaches to revolutionize cancer treatment, has recently achieved a significant milestone in their ongoing global Phase 3 study. The study aims to evaluate the potential of NBTXR3, a first-in-class radioenhancer, in elderly patients suffering from head and neck cancer. As a result of successfully meeting the study s operational requirements, strategic partner Janssen Pharmaceutica NV, a subsidiary of Johnson and Johnson, has awarded Nanobiotix with a substantial $20M milestone payment.
Promising Advances in Cancer Treatment:
Nanobiotix, known for its groundbreaking nanomedicine technology, focuses on developing innovative solutions to enhance cancer therapies. NBTXR3, their lead product candidate, is designed to improve the effectiveness of radiation therapy by amplifying its localized effects and minimizing the damage caused to healthy tissues surrounding tumors.

On the trailing twelve months basis NBTX Cash & cash equivalent improved by 6.06 % in Q4 2025 year on year, while Current Liabilities remained unchanged to $64 millions, this led to increase in in Nanobiotix S A 's Quick Ratio to 0.92, Quick Ratio remained below NBTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 481 other companies have achieved higher Quick Ratio than Nanobiotix S A . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3631 to 4581.

Explain Quick Ratio?
How much Cash & cash equivalents NBTX´s has?
What are NBTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 482
Healthcare Sector # 984
Within the Market # 4581


trailing twelve months Quick Ratio Statistics
High Average Low
6.26 1.95 0.84
(Dec 31 2020)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Genelux Corporation  2.52 $ 14.595  Millions$ 5.798  Millions
Xilio Therapeutics Inc   2.50 $ 137.531  Millions$ 54.930  Millions
Beone Medicines Ltd   2.49 $ 4,547.530  Millions$ 1,828.830  Millions
Processa Pharmaceuticals Inc   2.48 $ 5.537  Millions$ 2.236  Millions
Nextcure Inc   2.46 $ 25.982  Millions$ 10.566  Millions
Scienture Holdings Inc   2.44 $ 6.662  Millions$ 2.735  Millions
Hyperion Defi inc   2.39 $ 6.443  Millions$ 2.701  Millions
Nuvectis Pharma inc   2.38 $ 31.634  Millions$ 13.296  Millions
Seres Therapeutics Inc   2.37 $ 45.766  Millions$ 19.322  Millions
Satellos Bioscience Inc   2.35 $ 9.804  Millions$ 4.177  Millions
Insmed Inc  2.31 $ 1,430.047  Millions$ 618.925  Millions
Actuate Therapeutics Inc   2.31 $ 13.159  Millions$ 5.707  Millions
Elicio Therapeutics Inc   2.29 $ 18.563  Millions$ 8.110  Millions
Lantern Pharma Inc   2.29 $ 10.119  Millions$ 4.423  Millions
Palatin Technologies Inc   2.29 $ 14.476  Millions$ 6.333  Millions
Regeneron Pharmaceuticals Inc   2.26 $ 8,605.200  Millions$ 3,815.400  Millions
Ultragenyx Pharmaceutical Inc   2.24 $ 680.000  Millions$ 303.000  Millions
Corcept Therapeutics Inc  2.24 $ 372.152  Millions$ 166.085  Millions
Petros Pharmaceuticals inc   2.24 $ 5.137  Millions$ 2.293  Millions
Galectin Therapeutics Inc   2.22 $ 17.726  Millions$ 7.967  Millions
Prf Technologies Ltd   2.22 $ 5.207  Millions$ 2.348  Millions
Filana Therapeutics Inc   2.20 $ 95.502  Millions$ 43.470  Millions
Mustang Bio inc   2.18 $ 17.266  Millions$ 7.914  Millions
Dogwood Therapeutics inc   2.17 $ 6.525  Millions$ 3.002  Millions
Omeros Corporation  2.17 $ 171.804  Millions$ 79.208  Millions
Gossamer Bio Inc   2.16 $ 136.932  Millions$ 63.435  Millions
Larimar Therapeutics Inc   2.11 $ 136.852  Millions$ 64.795  Millions
Cue Biopharma Inc   2.09 $ 28.229  Millions$ 13.494  Millions
Schrodinger Inc   2.09 $ 395.464  Millions$ 189.136  Millions
Allarity Therapeutics Inc   2.09 $ 14.687  Millions$ 7.030  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.